{"id":170318,"date":"2025-08-19T06:45:09","date_gmt":"2025-08-19T10:45:09","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170318"},"modified":"2025-08-19T07:06:10","modified_gmt":"2025-08-19T11:06:10","slug":"biocon-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/biocon-q1-fy26-earnings-results\/","title":{"rendered":"Biocon Q1 FY26 Earnings Results"},"content":{"rendered":"<p>Biocon Limited, engaged in the manufacture of biotechnology products and research services, reported its <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/7be3f098-c01e-461e-af89-23b9691f2341.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> Earnings results.<\/p>\n<h2><strong>Q1 FY26 Earnings Results<\/strong><\/h2>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b93,942 crore, up 14.83% year-on-year (YoY) from \u20b93,433 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b93,925 crore, up 13.67% YoY from \u20b93,453 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b989 crore, down 89.68% from \u20b9862 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b90.23, down 95.81% from \u20b95.49 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li><strong>Strong Revenue Growth:<\/strong> Revenues increased by nearly 15%, driven by growth across biopharmaceuticals and research service segments.<\/li>\n<li><strong>Expense Rise:<\/strong> Expenses grew in line with revenue increase, reflecting higher operational activities and investments in R&amp;D.<\/li>\n<li><strong><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/7be3f098-c01e-461e-af89-23b9691f2341.pdf\" target=\"_blank\" rel=\"noopener\">Sharp Profit Decline<\/a><\/strong><strong>:<\/strong> Net profit and EPS plunged significantly due to one-time exceptional items or adverse non-operating factors impacting the bottom line.<\/li>\n<li><strong>Market Position:<\/strong> Biocon remains a leading biopharma player with diversified portfolios in biosimilars, novel biologics, and research services.<\/li>\n<li><strong>Strategic Initiatives:<\/strong> The company is focusing on expanding biosimilar offerings, enhancing global footprint, and accelerating innovation to drive long-term growth.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments in Q1 FY26 Earnings<\/strong><\/h2>\n<p>The quarter marked a challenging earnings phase for Biocon Ltd despite underlying revenue growth. The company is navigating operational complexities and non-recurring impacts while maintaining strategic focus.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-170319\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png\" alt=\"BIOCON Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>Biocon Ltd aims to leverage its strong R&amp;D pipeline, global biosimilar approvals, and strategic partnerships to revive profitability and sustain growth momentum through FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts,<a href=\"https:\/\/44.250.171.167\/symbol\/biocon\/\"> click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biocon Limited, engaged in the manufacture of biotechnology products and research services, reported its Q1 FY26 Earnings results. Q1 FY26 Earnings Results Revenue: \u20b93,942 crore, up 14.83% year-on-year (YoY) from \u20b93,433 crore in Q1 FY25. Total Expenses: \u20b93,925 crore, up 13.67% YoY from \u20b93,453 crore. Consolidated Net Profit (PAT): \u20b989 crore, down 89.68% from \u20b9862 [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":170319,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[3187],"class_list":["post-170318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-biotechnology"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172182,"url":"https:\/\/alphastreet.com\/india\/syngene-q2-fy26-earnings-results\/","url_meta":{"origin":170318,"position":0},"title":"Syngene Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 6, 2025","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Syngene Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170228,"url":"https:\/\/alphastreet.com\/india\/syngene-q1-fy26-earnings-results\/","url_meta":{"origin":170318,"position":1},"title":"Syngene Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 15, 2025","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Syngene Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169792,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1-fy26-earnings-results-51-rise-in-profits\/","url_meta":{"origin":170318,"position":2},"title":"Lupin Ltd Q1 FY26 Earnings Results &#8211; 51% rise in Profits","author":"Chirag Gupta","date":"August 6, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lupin Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172340,"url":"https:\/\/alphastreet.com\/india\/biocon-q2-fy26-earnings-results\/","url_meta":{"origin":170318,"position":3},"title":"Biocon Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 12, 2025","format":false,"excerpt":"Biocon Ltd, a prominent biotechnology company engaged in manufacturing biotechnology products and research services, reported extraordinary financial results for Q2FY26. Financial Highlights: Revenues grew 19.67% year-on-year to \u20b94,296 crore from \u20b93,590 crore. Total expenses increased 18.42% to \u20b94,205 crore from \u20b93,551 crore. Consolidated net profit skyrocketed 392.59% to \u20b9133 crore\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171141,"url":"https:\/\/alphastreet.com\/india\/dcw-q1-fy26-earnings-results\/","url_meta":{"origin":170318,"position":4},"title":"DCW Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 11, 2025","format":false,"excerpt":"DCW Ltd is engaged in the manufacture and sale of a diverse range of products with a focus on commodity chemicals, specialty chemicals, and intermediate products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results: Revenue: \u20b93,262 crore, up 13.42% year-on-year YoY from \u20b92,876 crore Total Expenses: \u20b93,114\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"DCW Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CW.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CW.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CW.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CW.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CW.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CW.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171158,"url":"https:\/\/alphastreet.com\/india\/delta-corp-q1-fy26-earnings-results\/","url_meta":{"origin":170318,"position":5},"title":"Delta Corp Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 11, 2025","format":false,"excerpt":"Delta Corp Ltd operates in the gaming, hospitality, and online skill gaming segments. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results: Revenue: \u20b9184 crore, up 3.37% year-on-year YoY from \u20b9178 crore Total Expenses: \u20b9158 crore, up 8.97% YoY from \u20b9145 crore Consolidated Net Profit PAT: \u20b929 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"DELTACORP Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/DELCORP.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/DELCORP.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/DELCORP.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/DELCORP.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/DELCORP.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/DELCORP.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170318"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170318\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170319"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}